NCT05933824View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Hiv
Interventions
DRUG

LP-98 injection

Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Trial Locations (1)

450000

Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital), Zhengzhou

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

lead

Shanxi Kangbao Biological Product Co., Ltd.

INDUSTRY